FIELD: biochemistry.
SUBSTANCE: invention relates to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 and a second compound selected from methyl 4-hydroxybenzoate or nicotinamide or ethyl gallate, or methyl gallate, or ethyl maltol, or vanillin, or (1R,2S,5R)-(-)-menthol. Molar ratio in the multicomponent crystalline system for the compound of formula 1 and the second compound is in the range of from 4:1 to 1:1. Multicomponent crystalline system of the invention is intended as an agent for the treatment of chronic myelogenous leukemia and/or acute lymphoblastic leukemia with the expression of the Philadelphia chromosome. 
.
EFFECT: multicomponent crystalline system has improved solubility.
13 cl, 7 dwg, 7 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND | 2010 |
|
RU2575173C2 |
| POLYMORPHOUS AND PSEUDOPOLYMORPHOUS FORMS OF THE PHARMACEUTICAL COMPOUND | 2010 |
|
RU2727509C2 |
| CRYSTAL FORM OF THE PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE | 2017 |
|
RU2793759C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| NOVEL CRYSTALLINE FORMS OF DIPEPTIDYLPEPTIDASE-IV INHIBITORS | 2012 |
|
RU2598072C2 |
| METHOD FOR PRODUCTION OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR COCRYSTALS | 2017 |
|
RU2779212C2 |
| CRYSTALS OF TAXANE DERIVATIVES AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2284328C2 |
| DASATINIB SALTS IN CRYSTALLINE FORM | 2014 |
|
RU2662805C2 |
| MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS | 2013 |
|
RU2652121C2 |
| SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-cd]INDOL-6-ONE | 2011 |
|
RU2570198C2 |
